M.D. Anderson Cancer Center
To learn if olutasidenib can help to control CCUS, MDS, and/or CMML. The safety of the drug will also be studied.
Primary Objectives - To determine the response rate of olutasidenib monotherapy in patients with IDH1-mutated CCUS or lower-risk MDS/CMML Secondary Objectives * To evaluate the rates of transfusion independence, defined as the absence of transfusions over a period of at least 8 weeks * To ascertain the safety and tolerability of olutasidenib monotherapy in these participants populations * To determine survival and rates of leukemia transformation * To analyze reduction in IDH1 clone size Exploratory Objectives \- To investigate global gene expression profiles, DNA methylation profiles, and…
Inclusion Criteria: To be considered eligible to participate in this study, a patient must meet ALL inclusion criteria as follows: 1. Pathologically proven CCUS or lower-risk MDS/CMML. 1. CCUS is defined as the presence of cytopenia (absolute neutrophil count \< 1.8 x 10\^9/L, hemoglobin \< 13 g/dL in males or \< 12 g/dL in females, and/or platelets \< 150 x 10\^9/L) for at least 30 days that are otherwise unexplained and with no diagnostic hematopathologic features of myeloid neoplasms. Patients with known Duffy-null phenotype must have absolute neutrophil counts less than their lower l…
Given by PO
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.